Trial Profile
Clinical efficacy and mechanism of Empagliflozin in the treatment of patients with new-onset type 2 diabetes and risk factor for atherosclerotic cardiovascular disease
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Apr 2022 Results (n=76) published in the Journal of Clinical Endocrinology and Metabolism
- 18 Oct 2018 New trial record